ClinicalTrials.gg

Program

efserakefusp alfa

Also written as “SHR-1501”, “SHR-1501+BCG” and “SHR-1501 for Injection”.

In Jiangsu HengRui Medicine's pipeline, IL-15. Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms · Neoplasms, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Feb 13, 20266 company-led studies, 4 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine64 open or runningphase 3since Feb 13, 2026May 9, 2019Dec 2027phase 2 · NCT07073534
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-1501, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 9, 2019First study: phase 1 study in Advanced MalignanciesFirst studyNCT03995472 · 14 enrolled · Australia, China
  2. Jul 14, 2019Phase 1 study in Advanced MalignanciesNCT04025957 · 19 enrolled · China
  3. May 19, 2022Phase 2 study in High-risk NMIBCNCT05410730 · 150 planned · China
  4. Jul 9, 2025Phase 2 study in NeoplasmsNCT07073534 · 203 planned · China
  5. Feb 13, 2026Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsPhase 3 reachedNCT07424287 · 236 planned · China
  6. Jul 21, 2026Phase 3 study in Papillary-Only Non-muscle-invasive Bladder CancerNCT07726992 · 750 planned · China

Ahead

  1. Dec 2027Primary completion: phase 2 study in NeoplasmsNCT07073534
  2. Dec 2029Primary completion: phase 3 study in Papillary-Only Non-muscle-invasive Bladder CancerNCT07726992
  3. Jun 2030Primary completion: phase 3 study in Non-Muscle Invasive Bladder NeoplasmsNCT07424287

TargetBeta

“IL-15”the company's pipeline, read by Claude · source
“A human Fc fusion protein composed of the cytokine interleukin (IL)-15 cross-linked with the high-affinity binding sushi domain of IL-15 receptor alpha (IL-15Ra), with potential antineoplastic activity. Upon administration, efserakefusp alfa activates and increases the levels of natural killer (N…”NCIt, read by Claude
“A human Fc fusion protein composed of the cytokine interleukin (IL)-15 cross-linked with the high-affinity binding sushi domain of IL-15 receptor alpha (IL-15Ra), ”NCIt, by rule

Other programs on IL15

ProgramCompanyFurthest phaseStudies
nogapendekin alfa inbakiceptruleImmunityBiophase 345
belacabnagene franleucelrulenkarta-incphase 23
GIA632Novartisphase 23
SPGL008rule3SBiophase 23
Daxokafusp AlfaSanofiphase 22

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07726992Papillary-Only Non-muscle-invasive Bladder Cancer · China3RecruitingDec 2029750
NCT07424287Non-Muscle Invasive Bladder Neoplasms · China3RecruitingJun 2030236
NCT07073534Neoplasms · China2RecruitingDec 2027203
NCT05410730High-risk NMIBC · China2RecruitingMay 2025150
NCT04025957Advanced Malignancies · China1CompletedJul 31, 202219
NCT03995472Advanced Malignancies · Australia, China1CompletedJan 12, 202314

How it is read

Names in the registry

  • “SHR-1501”, 3 entries
  • “SHR-1501+BCG”, 1 entry
  • “SHR-1501 for Injection”, 1 entry
  • “SHR-1501, Adebrelimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.